LifeMD, Inc. entered into a stock purchase agreement with new investor Jason Pharmaceuticals, Inc, wholly-owned subsidiary of Medifast, Inc. for issuance of 1,224,425 common shares at a price of $8.1671 per share for gross proceeds of approximately $10,000,000 on December 11, 2023. The issuance of shares of common stock in the private placement described above were made in reliance on the exemption from registration afforded under Section 4(a)(2) of the Securities Act of 1933, as amended and/or Rule 506 of Regulation D under the Securities Act. Medifast has invested $20 million into the company, including $10 million in contributions to support the collaboration, funding enhancements to the LifeMD platform, operations and supporting infrastructure, and a $10 million purchase of LifeMD?s common stock in the placement.